“Enhanced Efficiency Through Automation and Smart Analytics”
- A significant and accelerating trend in the global next generation biomanufacturing market is the integration of advanced automation and smart analytics platforms, which are streamlining production workflows and improving quality control across both clinical and commercial biologics manufacturing
- For instance, automated continuous bioreactors outfitted with IoT sensors and real-time monitoring systems allow manufacturers to collect live process data—such as pH, oxygen, and metabolite levels—and dynamically adjust parameters to maintain optimal cell culture conditions
- Such automation enables predictive maintenance and reduces batch variability. In-house platforms such as GE’s BioPharma Smart PLC systems and Siemens’ PharmaFAB solutions analyze performance trends and alert operators to anomalies before critical errors occur
- Moreover, smart data analytics tools are powering AI-driven process optimization—identifying bottlenecks, recommending scale-up strategies, and improving yield. For instance, Amgen reported yield improvements of up to 15% after deploying machine-learning models for upstream process control
- This shift toward more intelligent, data-driven, and fully automated biomanufacturing workflows is transforming traditional production paradigms. By reducing manual interventions and human error, facilities are achieving faster batch throughput and enhanced consistency
- Consequently, biopharma companies such as Pfizer and Novartis are investing heavily in “lights-out” manufacturing lines—with automated cell culture, filtration, and fill–finish—designed to run continuously and adaptively, meeting demand for complex therapeutics with greater reliability and at lower cost
